SUBSCRIBE
SUBSCRIBE
News   Drug Development

Johnson & Johnson Provides Added Doxil Supply for Clinical Studies

August 3, 2012 | 
1 min read
Johnson & Johnson (JNJ) will provide additional supply of its cancer drug Doxil for use in clinical trials, including one testing whether the combination of an experimental Endocyte Inc. (ECYT) drug with Doxil improves treatment of ovarian cancer.
Clinical research Postmarket research
Johnson & Johnson Family of Companies
MORE ON THIS TOPIC
Podcast
Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs
February 4, 2026
 · 
1 min read
 · 
Heather McKenzie
A close-up of a zebra standing in the Okavango Delta, showcasing its distinctive black and white stripes. The background is a blur of natural vegetation.
Insights
From Awareness to Acceleration: Rare Disease Drug Development Enters a Pivotal Era
February 4, 2026
 · 
3 min read
 · 
Jennifer Smith-Parker
Mechanical weight scale, body mass control concept : Bathroom scale on pale blue wood background. Analog scale operated with spring that pressure is calibrated to translate tension into a mass readout.
Obesity
Pfizer’s First Weight-Loss Data After Metsera Buy ‘Look Competitive’
February 3, 2026
 · 
2 min read
 · 
Tristan Manalac
Life is full of challenges and unexpected obstacles. Use these experiences as motivation to keep pushing forward and striving for your goals
Antibody-drug conjugate (ADC)
Daiichi Sankyo Dumps Next-Gen ADC From Development Pipeline
February 3, 2026
 · 
2 min read
 · 
Tristan Manalac